Predicting the safety and toxicity of your drug candidates in a human liver environment with the PXB-mouse® model.
It is estimated that almost 50% of drug candidates fail because of unacceptable efficacy, and 40% fail due to toxicity. One reason for these high failure rates is the types of preclinical models used — conventional animal models often poorly predict the efficacy and toxicity of a drug candidate within human environments due to intrinsic, species-specific differences.
That’s why we developed the PXB-mouse®, a chimeric mouse model with a humanized liver to help you understand how your drug candidates perform in a human environment. Our PXB-mouse® is the ideal animal model for DMPK/toxicity studies due to its high and stable expression of human enzymes and transporters, providing powerful predictive insight into human physiology in the convenience of a mouse model.
De-risk your compound selection and predict human outcomes more accurately to enable the development of safe, effective, and compliant formulations with our PXB-mouse® model. Combined with our team of experts, and their access to comparison data and publications, we can help you to demonstrate the benefits of using this highly predictive mouse model within your niche research area.
Building from over 15 years of experience, our in-house and partner study services use PXB-mice to provide comprehensive predictions of human pharmacokinetics — even with compounds implicated in complex metabolic pathways. This means you can better de-risk your compound and predict human outcomes more accurately.
We apply our model within the DMPK research space to increase your confidence during lead candidate compound selection by providing insights into potential human outcomes of pharmacokinetics and human-specific hepatotoxicity.
Our PXB-mice have increased the translational potential of many DMPK/Toxicity studies over the past 15 years: